- Home
- NUW vs GOSS Comparison
NUW vs GOSS Comparison
Compare NUW & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- GOSS
- Stock Information
- Founded
- NUW 2008
- GOSS 2015
- Country
- NUW United States
- GOSS United States
- Employees
- NUW N/A
- GOSS N/A
- Industry
- NUW Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- NUW Finance
- GOSS Health Care
- Exchange
- NUW Nasdaq
- GOSS Nasdaq
- Market Cap
- NUW 256.2M
- GOSS 214.7M
- IPO Year
- NUW N/A
- GOSS 2019
- Fundamental
- Price
- NUW $14.27
- GOSS $0.96
- Analyst Decision
- NUW
- GOSS Strong Buy
- Analyst Count
- NUW 0
- GOSS 5
- Target Price
- NUW N/A
- GOSS $9.20
- AVG Volume (30 Days)
- NUW 45.3K
- GOSS 943.4K
- Earning Date
- NUW 01-01-0001
- GOSS 11-07-2024
- Dividend Yield
- NUW 3.66%
- GOSS N/A
- EPS Growth
- NUW N/A
- GOSS N/A
- EPS
- NUW N/A
- GOSS N/A
- Revenue
- NUW N/A
- GOSS $95,842,000.00
- Revenue This Year
- NUW N/A
- GOSS N/A
- Revenue Next Year
- NUW N/A
- GOSS N/A
- P/E Ratio
- NUW N/A
- GOSS N/A
- Revenue Growth
- NUW N/A
- GOSS N/A
- 52 Week Low
- NUW $12.45
- GOSS $0.45
- 52 Week High
- NUW $14.44
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- NUW 59.14
- GOSS 46.59
- Support Level
- NUW $14.22
- GOSS $0.93
- Resistance Level
- NUW $14.38
- GOSS $1.09
- Average True Range (ATR)
- NUW 0.08
- GOSS 0.05
- MACD
- NUW -0.01
- GOSS -0.01
- Stochastic Oscillator
- NUW 70.37
- GOSS 12.38
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.